CytoMed Therapeutics (GDTC) Income Statement (2020 - 2025)
Income Statement report data from Mar 31, 2020 to Dec 31, 2025 for CytoMed Therapeutics (GDTC) in SGD with ability to convert in USD.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||||||||||||
Total Revenue | 170K (-19.05%) | 210K (+61.54%) | 130K (0.00%) | 130K (-7.14%) | 140K (+27.27%) | 110K (0.00%) | 110K | - | 110K (-21.43%) | 140K (0.00%) | 140K | - | 140K (+250.00%) | 40K (0.00%) | 40K (0.00%) | 40K (0.00%) | 40K | - | 10K (-66.67%) | 30K (0.00%) | 30K | - | - |
Cost Of Revenue | 720K (+2300.00%) | 30K (+200.00%) | 10K (0.00%) | 10K (0.00%) | 10K | - | - | 40K | - | 210K | - | 40K | - | 60K | - | 50K | - | 50K | -70.00K | - | - | - | - |
Costof Goods And Services Sold | 720K (+2300.00%) | 30K (+200.00%) | 10K (0.00%) | 10K (0.00%) | 10K | - | - | 40K | - | 210K | - | 40K | - | 60K | - | 50K | - | 50K | -70.00K | - | - | - | - |
Gross Profit | -560.00K | 170K (+30.77%) | 130K (0.00%) | 130K (0.00%) | 130K (+18.18%) | 110K (0.00%) | 110K | -40.00K | 110K | -60.00K | 140K | -40.00K | 140K | -60.00K | 40K | -50.00K | 40K | -50.00K | 10K (-66.67%) | 30K (0.00%) | 30K | - | - |
Operating Expenses | |||||||||||||||||||||||
Research And Development | 1.05M (+98.11%) | 530K (-8.62%) | 580K (0.00%) | 580K (+23.40%) | 470K (-45.35%) | 860K (+75.51%) | 490K (-15.52%) | 580K (+48.72%) | 390K (-4.88%) | 410K (+2.50%) | 400K (-39.39%) | 660K (+43.48%) | 460K (+53.33%) | 300K (0.00%) | 300K (-47.37%) | 570K (+103.57%) | 280K (-47.17%) | 530K (+103.85%) | 260K (-21.21%) | 330K (0.00%) | 330K (+73.68%) | 190K (0.00%) | 190K |
Selling General And Administrative | - | 290K | - | 160K (0.00%) | 160K (+6.67%) | 150K (0.00%) | 150K | - | 150K (-77.94%) | 680K (+871.43%) | 70K | - | - | - | - | 50K (0.00%) | 50K | - | - | 40K | - | - | - |
Operating Expenses | 1.80M (+116.87%) | 830K (+6.41%) | 780K (0.00%) | 780K (+20.00%) | 650K (+1.56%) | 640K (0.00%) | 640K (-56.76%) | 1.48M (+169.09%) | 550K (+12.24%) | 490K (0.00%) | 490K (-50.51%) | 990K (+90.38%) | 520K (-40.23%) | 870K (+148.57%) | 350K (-65.35%) | 1.01M (+206.06%) | 330K (-57.14%) | 770K (+156.67%) | 300K (-21.05%) | 380K (+2.70%) | 370K (+76.19%) | 210K (-4.55%) | 220K |
Depreciation And Amortization | 130K (+30.00%) | 100K (+11.11%) | 90K (0.00%) | 90K (+12.50%) | 80K (-52.94%) | 170K (+112.50%) | 80K (+100.00%) | 40K (-55.56%) | 90K (-57.14%) | 210K (+110.00%) | 100K (+150.00%) | 40K (-60.00%) | 100K (+66.67%) | 60K (-40.00%) | 100K (+100.00%) | 50K (-37.50%) | 80K (+60.00%) | 50K (-37.50%) | 80K (0.00%) | 80K (0.00%) | 80K (+14.29%) | 70K (0.00%) | 70K |
Operating Income | |||||||||||||||||||||||
Operating Income | -2.36M (+257.58%) | -660.00K (+1.54%) | -650.00K (0.00%) | -650.00K (+25.00%) | -520.00K (-1.89%) | -530.00K (0.00%) | -530.00K (-65.13%) | -1.52M (+245.45%) | -440.00K (-72.15%) | -1.58M (+56.44%) | -1.01M (-1.94%) | -1.03M (+178.38%) | -370.00K (+15.63%) | -320.00K (0.00%) | -320.00K (-70.09%) | -1.07M (+268.97%) | -290.00K (-64.63%) | -820.00K (+182.76%) | -290.00K (-17.14%) | -350.00K (+2.94%) | -340.00K (+61.90%) | -210.00K (-4.55%) | -220.00K |
Ebit | -2.36M (+114.55%) | -1.10M (-1.79%) | -1.12M (0.00%) | -1.12M (+49.33%) | -750.00K (-31.82%) | -1.10M (+32.53%) | -830.00K (-45.39%) | -1.52M (+67.03%) | -910.00K (-57.08%) | -2.12M (+109.90%) | -1.01M (-1.94%) | -1.03M (+101.96%) | -510.00K (-45.16%) | -930.00K (+121.43%) | -420.00K (-44.00%) | -750.00K (+53.06%) | -490.00K (-50.00%) | -980.00K (+157.89%) | -380.00K (-5.00%) | -400.00K (0.00%) | -400.00K (+53.85%) | -260.00K (0.00%) | -260.00K |
EBITDA | -2.22M (+122.00%) | -1.00M (-2.91%) | -1.03M (0.00%) | -1.03M (+53.73%) | -670.00K (-27.96%) | -930.00K (+25.68%) | -740.00K (-50.00%) | -1.48M (+80.49%) | -820.00K (-57.29%) | -1.92M (+110.99%) | -910.00K (-8.08%) | -990.00K (+141.46%) | -410.00K (-52.87%) | -870.00K (+171.88%) | -320.00K (-54.29%) | -700.00K (+75.00%) | -400.00K (-56.99%) | -930.00K (+210.00%) | -300.00K (-6.25%) | -320.00K (0.00%) | -320.00K (+68.42%) | -190.00K (0.00%) | -190.00K |
Other Income / Expenses | |||||||||||||||||||||||
Interest Expense | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K | - | 10K (0.00%) | 10K (0.00%) | 10K | - | 40K (-33.33%) | 60K (+20.00%) | 50K | - | 60K | - | 60K (+100.00%) | 30K (-50.00%) | 60K (+100.00%) | 30K (0.00%) | 30K (0.00%) | 30K (+50.00%) | 20K (0.00%) | 20K |
Net Income | |||||||||||||||||||||||
Income Before Tax | -1.74M (+97.73%) | -880.00K (-22.12%) | -1.13M (0.00%) | -1.13M (+54.79%) | -730.00K (+35.19%) | -540.00K (-1.82%) | -550.00K (-62.07%) | -1.45M (+46.46%) | -990.00K (-54.79%) | -2.19M (+102.78%) | -1.08M (-28.95%) | -1.52M (+42.06%) | -1.07M (+114.00%) | -500.00K (0.00%) | -500.00K (-50.98%) | -1.02M (+100.00%) | -510.00K (-50.96%) | -1.04M (+103.92%) | -510.00K (-27.14%) | -700.00K (0.00%) | -700.00K (+169.23%) | -260.00K (-3.70%) | -270.00K |
Income Tax Expense | - | - | - | - | - | 570K | - | - | - | 10K | - | - | - | 20K | - | 160K | - | - | - | - | - | - | - |
Net Income | -1.73M (+98.85%) | -870.00K (-23.01%) | -1.13M (+0.89%) | -1.12M (+55.56%) | -720.00K (-34.55%) | -1.10M (+100.00%) | -550.00K (-62.33%) | -1.46M (+47.47%) | -990.00K (-8.33%) | -1.08M (0.00%) | -1.08M (-29.41%) | -1.53M (+42.99%) | -1.07M (+5.94%) | -1.01M (+102.00%) | -500.00K (-50.98%) | -1.02M (+100.00%) | -510.00K (-50.96%) | -1.04M (+103.92%) | -510.00K (-27.14%) | -700.00K (0.00%) | -700.00K (+169.23%) | -260.00K (-3.70%) | -270.00K |